When the Kansas City Chiefs and Philadelphia Eagles took the field for Super Bowl LX this February, they shared the spotlight with an unexpected player: the pharmaceutical industry. For decades, healthcare brands treated the Big Game as off-limits—a blazingly expensive platform ill-suited to the regulatory minefields of drug advertising. But this year’s broadcast told a different story. Novo Nordisk, Eli Lilly, and a handful of other health giants claimed prime real estate during television’s most-watched event, trading traditional symptom-and-solution formats for something far more elusive: cultural resonance.

The shift didn’t go unnoticed. Viewers engaged deeply with ads that focused less on clinical data and more on lived experience, less on mechanism and more on meaning. Novo Nordisk’s spot landed in the top ten for audience engagement, a remarkable feat for a category long consigned to the margins of consumer consciousness. Yet even as the industry celebrated its mainstream moment, the US Food and Drug Administration (FDA) issued a warning letter to Novo Nordisk—not for its Super Bowl creative, but for implications baked into its broader messaging campaign. The timing couldn’t have been more pointed.

To understand what this moment means for the future of health marketing, Drug and Device World spoke with Heather Coyle, President at Triggers, a behavioral science-driven brand strategy firm. With 35 years in pharma marketing and a personal mission shaped by her own experience as a cancer survivor, Coyle offers a uniquely grounded perspective on how the industry is finally learning to speak human.

Pharma Bowl: The Cultural Tipping Point

The term “Pharma Bowl” surfaced on social media during the Super Bowl broadcast, a half-joking nod to the sudden saturation of healthcare advertising. But for Coyle, the phenomenon was anything but accidental.

“It reflected something bigger than marketing ambition,” she explains. “What has really fundamentally changed is cultural centrality.”

That centrality, she argues, begins with obesity, a condition that has migrated from private struggle to public conversation with stunning speed. “When a therapy becomes part of dinner table dialogues, celebrity commentary, social media identity, it stops behaving like a niche therapeutic category and starts behaving like a mainstream consumer brand category.”

The distinction matters because it signals a fundamental rewrite of pharma’s marketing playbook. For generations, drug advertising operated on an informational model: identify a symptom, present a solution, recite the risks. The formula was functional but forgettable, designed more for compliance than connection. This year’s Super Bowl ads abandoned that template entirely.

The DTC Playbook

“The most effective brands today understand that behavior doesn’t change because of information,” Coyle says. “It changes because of identity alignment or emotional permission.”

That insight has driven health brands toward strategies long perfected in consumer packaged goods: leading with lived experience rather than mechanism, translating clinical benefit into life impact, and making change feel socially validated. Novo Nordisk’s approach to destigmatization proved particularly telling. By framing obesity as a chronic disease rather than a personal failing, the company offered something traditional pharma advertising rarely attempts: permission.

“Permission for patients to ask about treatment,” Coyle elaborates. “Permission for physicians to escalate care. Permission for brands to speak at scale.”

The Super Bowl, in this reading, ceases to function merely as media inventory. It becomes a cultural declaration. A signal that certain conditions are no longer fringe, that they deserve not just clinical attention but social acknowledgment. When colon cancer detection or chronic kidney disease claim space between beer commercials and automotive spotlights, the message extends beyond any individual product. “It’s not a conversion play,” Coyle emphasizes. “It’s a legitimacy play.”

Emotional Resonance Meets Regulatory Reality

Yet legitimacy, in a heavily regulated industry, walks a narrow line. The emotional resonance that makes an ad memorable can also make it vulnerable to regulatory scrutiny. And no recent example illustrates that tension more vividly than the FDA’s response to Novo Nordisk’s broader campaign.

The February warning letter took issue not with explicit claims but with implications. Phrases like “live lighter” and “a way forward,” the FDA argued, suggested broader life transformation and unapproved psychological benefits. The agency also flagged language that could be interpreted as implying superior efficacy over other GLP-1 drugs, a claim unsupported by head-to-head data.

For Coyle, the episode underscores a reality that pharma marketers can no longer afford to ignore. “This is not about recklessness on behalf of Novo Nordisk,” she clarifies. “It is about how far lifestyle framing can stretch before it becomes an implication that’s problematic.”

The distinction between explicit claims and engineered inference has become the industry’s new frontier. When a drug sits at the intersection of identity and aspiration, as GLP-1s increasingly do, emotional framing naturally gravitates toward transformation. The brain automatically fills gaps that advertising merely suggests. And that automatic filling, Coyle argues, is precisely where behavioral science meets regulatory reality.

Engineering Inference

“The most sophisticated pharma brands are not pushing the boundaries of compliance,” she explains. “They are using behavioral science to work within it.”

Her firm specializes in precisely this territory: deploying metaphor, contrast, and instinctive visual cues to activate meaning without overextension. Contrast works because the human brain processes difference faster than description. Metaphors carry instinctive weight that dense claims cannot match. The goal is cognitive efficiency—communicating complex information through implication rather than exposition.

“When you think about a high-cost, high-visibility moment like the Super Bowl,” Coyle notes, “you cannot rely on dense claims. You need cognitive efficiency.”

This year’s most effective ads demonstrated exactly that discipline. They used behavioral science tools to navigate compliance challenges elegantly, communicating meaning without triggering regulatory alarms. But the Novo Nordisk letter raises the stakes considerably. If implication carries as much weight as explicit language, then every creative choice becomes a compliance decision.

“It’s maybe less of a warning shot and more of a reminder,” Coyle reflects. “Brands are going to have to get significantly more sophisticated with understanding what implications will be interpreted not just by consumers, but by the FDA.”

That sophistication will likely take several forms: tighter anchoring of metaphor to labeled benefits, careful use of contrast without implied cures, activation of instinctive meaning without indication expansion. The brands that master these moves will win not by retreating from emotional resonance but by engineering it more precisely.

“The future of compliant advertising isn’t about your disclaimers,” Coyle insists. “It’s about disciplined semiotics.”

The Road Ahead

The broader context for these developments extends well beyond the Super Bowl. Coyle traces the current moment back to COVID-19, when average consumers suddenly found themselves discussing mRNA with the fluency of biochemistry students. That unexpected intimacy with scientific complexity normalized conversations that would have seemed unthinkable a decade earlier.

More immediately, the explosion of GLP-1 discourse across social media created demand that traditional physician-directed marketing could never satisfy. Influencers discussed weight loss, patients compared experiences, and brands recognized an unprecedented opportunity. Before the recent surge, consumer health divisions at major pharmaceutical companies often struggled. Now they command attention and investment.

“I think the economics for a lot of these brands are too large for them to retreat,” Coyle observes. “They are going to have to become more sophisticated.”

That sophistication will manifest across multiple dimensions. Coyle predicts a shift from performance-focused DTC advertising toward genuine brand building—identity-led healthcare marketing that treats patients as participants rather than recipients. She expects more normalization campaigns in stigmatized categories, following the template this year’s Super Bowl ads established. And she anticipates continued tension between cultural ambition and regulatory constraint, with the industry’s sharpest players learning to navigate both.

“The future isn’t pharma choosing between HCPs (Health Care Professionals) and consumers,” she says. “It’s recognizing that belief formation happens well before the prescription is written.”

Why Better Communication Matters

For Coyle personally, this evolution carries weight beyond professional interest. A cancer survivor herself, she speaks of healthcare communication with urgency that transcends marketing metrics. When patients receive a diagnosis, particularly of a chronic condition, the information landscape can feel impossibly overwhelming. Tools that help people understand their conditions and treatments, that position them as partners in their own care, represent genuine progress.

“Seeing the industry finally moving toward adopting these really effective tools is heartwarming,” she admits. “It’ll benefit the entire healthcare system when people have better access to information.”

Yet she also sees room for growth. Pharma still lags other industries in deploying distinctive brand assets—cognitive codes and cues that ensure messaging gets attributed correctly. Staggering amounts of data show how few brands use these tools effectively, how often their messages become category benefits rather than brand properties. Competitors reap what others sow.

“I am hopeful that brands will start to incorporate more of that,” Coyle says, “so they themselves get the credit for their product rather than just serving as an awareness campaign.”

The Meaning of the Moment

Coyle notes that her thirty-five years in pharma marketing have taught her to recognize genuine change when she sees it. The shift from drug-focused, claim-heavy advertising toward lifestyle and personal identity represents something she has never witnessed before.

“That’s a massive shift for this industry,” she says. “It signals a much bigger shift in how the industry is thinking about marketing and about its target audience—in a really profound, much better, more human-centric way.”

Whether the industry fully recognizes what it has begun remains an open question. The Super Bowl ads signaled arrival; the FDA letter signaled vigilance. Between them lies the territory where healthcare marketing will either flourish or flounder. The brands that thrive will be those that learn to speak simultaneously to regulators and to human beings—that understand compliance not as constraint but as creative discipline.